NewEdge Wealth LLC Has $2.13 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

NewEdge Wealth LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,564 shares of the company’s stock after acquiring an additional 2,530 shares during the period. NewEdge Wealth LLC’s holdings in AstraZeneca were worth $2,126,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca during the second quarter worth $25,000. ICA Group Wealth Management LLC acquired a new stake in AstraZeneca in the fourth quarter worth $26,000. Anchor Investment Management LLC acquired a new stake in AstraZeneca in the fourth quarter worth $26,000. Parkside Financial Bank & Trust grew its holdings in AstraZeneca by 4,875.0% in the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after purchasing an additional 390 shares during the period. Finally, Compagnie Lombard Odier SCmA acquired a new stake in AstraZeneca in the fourth quarter worth $27,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on AZN. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Jefferies Financial Group cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Morgan Stanley began coverage on shares of AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating for the company. Finally, HSBC began coverage on shares of AstraZeneca in a report on Monday, December 18th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $80.00.

AstraZeneca Stock Down 0.7 %

AZN opened at $68.93 on Monday. The firm has a market capitalization of $213.71 billion, a P/E ratio of 35.90, a PEG ratio of 1.26 and a beta of 0.50. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.82 and a quick ratio of 0.64. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $76.56. The company’s 50-day moving average is $65.89 and its 200 day moving average is $65.82.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.01). The company had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 EPS. Research analysts expect that AstraZeneca PLC will post 4.02 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were given a $0.965 dividend. This is a positive change from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a yield of 2.3%. AstraZeneca’s payout ratio is currently 100.52%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.